The trending topic of data transparency has been making news recently. The European Federation of Pharmaceutical Industries (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) have agreed to make their clinical trial data more readily available for public inquiry. Our Founder and CEO, Yin Ho, was asked to comment on this recently, in a Specialty Pharmacy Times piece, "Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions."
In the article, she provided an analogy comparing the process of how to interpret publicly shared data to viewing megapixels in a high resolution picture. “In the case of patient-level data, that would be like clearly seeing the individual pixels in a high-resolution picture without knowing the relationship of the pixels to each other."
Her analysis brings out the core issue of data transparency: the problem of laying out all of this data without giving the user some type of background or understanding as to what they are looking at, or as she stated it "Without the proper context, transparency on its own is meaningless."